Benefits
Memory enhancement in healthy adults (BT-11 RCT)
Lee 2009 (PMID 19429065, Phytomedicine) randomized double-blind placebo-controlled parallel-group study in healthy Korean adults given BT-11 (Polygala tenuifolia root extract) capsules 3x daily for 4 weeks. Verbal memory (Korean version California Verbal Learning Test) and working memory (Self-Ordered Pointing Test) measured. RESULT: BT-11 improved memory in healthy humans vs placebo. Foundational human trial supporting cognitive enhancement claim.
Cognitive enhancement in elderly (BT-11 RCT)
Shin 2009 (PMID 19699261, Phytother Res) randomized double-blind placebo-controlled comparison in elderly humans given BT-11 (n=28) vs placebo (n=25). CERAD (Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet) and MMSE used. RESULT: Total CERAD scores significantly more increased in BT-11 group than placebo. Demonstrates extension of cognitive benefit to elderly population — directly relevant to age-related cognitive decline application.
Alzheimer's disease (TCM combination evidence)
Zhang 2024 systematic review (PMC10815298) of Polygala tenuifolia + Acorus tatarinowii combination for Alzheimer's disease included multiple Chinese RCTs. Outcomes: MMSE, ADL, ADAS-cog. Combination showed efficacy improvements over control conditions in pooled analysis. Limited by Chinese RCT methodology concerns and combination-product attribution issues — but provides supporting context for TCM cognitive use.
Sedative and anxiolytic activity (traditional)
TCM uses Polygala for insomnia, palpitations, restlessness, anxiety — alongside cognitive enhancement, an unusual combination of indications. Mechanistically supported by polygalasaponin GABA-modulating activity. Limited human RCT evidence specifically for anxiety/sleep but consistent traditional use across centuries.
Neuroprotection (preclinical evidence)
Tenuigenin, tenuifolin, polygalasaponins, and onjisaponin B demonstrate β-amyloid reduction, antioxidant effects, neurotransmitter regulation, synaptic function improvement, anti-inflammatory effects, neuronal apoptosis inhibition, and autophagy modulation in animal models of dementia, Alzheimer's, and Parkinson's. Mechanistic foundation stronger than human RCT base.
Mechanism of action
Acetylcholinesterase inhibition (cholinergic enhancement)
Polygala tenuifolia extract demonstrates acetylcholinesterase inhibitory activity in vitro — increasing synaptic acetylcholine availability. Mechanism comparable to (but weaker than) donepezil-class Alzheimer's drugs. Supports cognitive enhancement claims via cholinergic pathway involved in encoding new information.
BDNF and MAP kinase pathway activation
Polygalasaponin XXXII (PGS32) and other actives activate ERK/CREB pathway leading to elevated brain-derived neurotrophic factor (BDNF) — key for synaptic plasticity, neurogenesis, and cognitive function. Long-term potentiation (LTP) enhancement in dentate gyrus electrophysiology. Mechanism for sustained cognitive benefit beyond acute cholinesterase inhibition.
GABA-modulating activity (sedative effects)
Polygalasaponins extract shows GABAergic modulation — anxiolytic and sedative-hypnotic activities in animal models. Mechanism for traditional sedative/anti-anxiety uses. May cause mild sedation in some users — consistent with TCM use for insomnia and 'calming the heart-spirit.'
Nerve growth factor (NGF) release enhancement
P. tenuifolia extract enhances NGF release from astroglial cells — supporting neuronal survival, growth, and synaptic maintenance. Combined with BDNF effects, produces broader neurotrophic support relevant to age-related cognitive decline and dementia prevention. Direct human translation limited.
Clinical trials
Randomized double-blind placebo-controlled parallel-group study (Lee JY, Kim KY, Shin KY, Won BY, Jung HY, Suh YH 2009, Phytomedicine 16(8):700-704, doi:10.1016/j.phymed.2009.04.001, PMID 19429065).
Healthy Korean adults received BT-11 (Polygala tenuifolia Willdenow root extract) capsules or placebo 3 times daily for 4 weeks. Korean version of California Verbal Learning Test (K-CVLT) for verbal memory and Self-Ordered Pointing Test (SOPT) for working memory.
BT-11 enhanced memory in healthy humans vs placebo on cognitive testing. Foundational positive trial demonstrating cognitive enhancement effect of standardized P. tenuifolia extract in cognitively normal adults. Translates extensive preclinical animal evidence (scopolamine-/stress-induced amnesia models) to humans.
Randomized double-blind placebo-controlled comparison (Shin KY, Lee JY, Won BY, Jung HY, Chang KA, Koppula S, Suh YH 2009, Phytother Res 23(11):1561-1564, doi:10.1002/ptr.2802, PMID 19699261).
Elderly humans randomized to BT-11 (n=28) or placebo (n=25). Used CERAD (Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet) and MMSE assessments.
Total CERAD scores significantly more increased in BT-11-treated group than in placebo group. Demonstrates cognitive enhancement extends to elderly population — most relevant clinical context for age-related cognitive decline applications. Replicates and extends Lee 2009 healthy adult finding.
Systematic review and meta-analysis (Zhang Y, Tian J, Ni J, Wei M, Li T, Shi J 2024, Front Pharmacol 14:1268000, doi:10.3389/fphar.2023.1268000). PMC10815298. PROSPERO registered.
Systematic review of Chinese RCTs of Polygala tenuifolia + Acorus tatarinowii combination treatment for Alzheimer's disease. 8 databases searched. Outcomes: MMSE, ADL, ADAS-cog. Cochrane risk of bias assessment.
Combination improved cognitive measures (MMSE, ADAS-cog) and functional measures (ADL) in pooled analysis. Limited by methodological quality concerns of Chinese RCTs and combination-product attribution. Provides systematic review evidence for the most common TCM cognitive combination using Polygala.